ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 711,61
0,34%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. Bio Rad Laboratories Inc (BIO)

  7. Bio Rad Laboratories Inc (BIO) Actualités

BIO

Bio Rad Laboratories (BIO)

Bio Rad Laboratories Inc
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:BIO
DateHeureSourceTitreSymboleSociété
30/05/202415h00Business WireBio-Rad Names Anette Engelhardt Executive Vice President and President of Clinical Diagnostics GroupNYSE:BIOBio Rad Laboratories Inc
23/05/202422h15Business WireBio-Rad’s Management to Participate in Fireside Chat During Jefferies Global Healthcare ConferenceNYSE:BIOBio Rad Laboratories Inc
09/05/202422h30Edgar (US Regulatory)Form SD - Specialized disclosure reportNYSE:BIOBio Rad Laboratories Inc
08/05/202422h38Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNYSE:BIOBio Rad Laboratories Inc
08/05/202422h31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:BIOBio Rad Laboratories Inc
08/05/202420h25Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNYSE:BIOBio Rad Laboratories Inc
07/05/202422h18Edgar (US Regulatory)Form 8-K - Current reportNYSE:BIOBio Rad Laboratories Inc
07/05/202422h15Business WireBio-Rad Reports First-Quarter 2024 Financial ResultsNYSE:BIOBio Rad Laboratories Inc
01/05/202415h00Business WireBio-Rad’s Management to Participate in Fireside Chat During RBC Capital Markets Global Healthcare ConferenceNYSE:BIOBio Rad Laboratories Inc
26/04/202414h30Business WireBio-Rad Announces Life Science Group Management ChangesNYSE:BIOBio Rad Laboratories Inc
18/04/202415h00Business WireBio-Rad to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024NYSE:BIOBio Rad Laboratories Inc
11/04/202423h30GlobeNewswire Inc.Oncocyte and Bio-Rad Partner on Global Launch of Transplant AssayNYSE:BIOBio Rad Laboratories Inc
10/04/202422h15Business WireBio-Rad’s Chief Operating Officer Andrew Last to RetireNYSE:BIOBio Rad Laboratories Inc
20/03/202413h30Business WireBio-Rad Appoints Roop K. Lakkaraju Executive Vice President, Chief Financial OfficerNYSE:BIOBio Rad Laboratories Inc
22/02/202422h30Business WireBio-Rad to Participate in Fireside Chat During Citi's 2024 Unplugged Medtech and Life Sciences Access DayNYSE:BIOBio Rad Laboratories Inc
15/02/202422h15Business WireBio-Rad Reports Fourth-Quarter and Full-Year 2023 Financial ResultsNYSE:BIOBio Rad Laboratories Inc
24/01/202423h00Business WireBio-Rad to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024NYSE:BIOBio Rad Laboratories Inc
02/01/202422h15Business WireBio-Rad’s Management to Host Investor Meetings at J.P. Morgan’s 42nd Annual Healthcare ConferenceNYSE:BIOBio Rad Laboratories Inc
26/10/202322h15Business WireBio-Rad Reports Third-Quarter 2023 Financial ResultsNYSE:BIOBio Rad Laboratories Inc
05/10/202314h30Business WireBio-Rad to Report Third Quarter 2023 Financial Results on Thursday, October 26, 2023NYSE:BIOBio Rad Laboratories Inc
28/08/202322h15Business WireBio-Rad to Participate in Fireside Chat During Wells Fargo’s 2023 Healthcare ConferenceNYSE:BIOBio Rad Laboratories Inc
03/08/202322h15Business WireBio-Rad Reports Second-Quarter 2023 Financial ResultsNYSE:BIOBio Rad Laboratories Inc
26/07/202322h15Business WireBio-Rad and QIAGEN Announce Patent Settlement and Cross-Licensing AgreementNYSE:BIOBio Rad Laboratories Inc
20/07/202322h30Business WireBio-Rad Announces New Share Repurchase ProgramNYSE:BIOBio Rad Laboratories Inc
10/07/202322h30Business WireBio-Rad to Report Second Quarter 2023 Financial Results on Thursday, August 3, 2023NYSE:BIOBio Rad Laboratories Inc
10/07/202315h00Business WireBio-Rad Publishes Corporate Sustainability Report for 2022NYSE:BIOBio Rad Laboratories Inc
15/06/202323h13Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NYSE:BIOBio Rad Laboratories Inc
07/06/202317h32Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:BIOBio Rad Laboratories Inc
05/06/202314h46Edgar (US Regulatory)Current Report Filing (8-k)NYSE:BIOBio Rad Laboratories Inc
01/06/202314h00Business WireBio-Rad to Present Company Overview at Jefferies Healthcare ConferenceNYSE:BIOBio Rad Laboratories Inc
 Showing the most relevant articles for your search:NYSE:BIO

Dernières Valeurs Consultées

LSE
44MF
Assa 21
NASDAQ
FXCOU
Financial Strategies Acq...
BIT
P12VB2
BNP PARIBAS ISSUANCE
BIT
BDB
Banco Di Desio E Della B...
BIT
MUV2
Muenchener Rueckversiche...
BIT
AL7575
Banca Aletti and C
BIT
S27209
Societe Generale Effekten
BIT
ACE
Acea
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés